

Visugromab Biosimilar - Research Grade

Product Code: ICH5286

More Information

Species Reactivity: Human

Target: GDF15

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Visugromab Biosimilar - Research Grade

Antibodies against the same target: [Ponsegromab Biosimilar - Research Grade \(ICH5182\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q99988

Shipping Conditions: Blue ice

background: This product is a research-grade biosimilar of visugromab (development code CTL-002), supplied as an unconjugated, non-therapeutic analog built around the GDF15 target. It is a human IgG4-kappa molecule intended for research use only and is not a clinical drug. Visugromab is an investigational neutralizing antibody directed against GDF15 (growth differentiation factor 15), studied clinically as a monotherapy and in combination with anti-PD-1 checkpoint blockade in advanced, relapsed or refractory solid tumors, where high GDF15 in the tumor microenvironment is associated with immune evasion and cancer-associated cachexia. Because the antibody neutralizes soluble circulating GDF15, this reagent is well suited to functional and in-vitro work such as ligand-neutralization assays, blockade of GDF15-driven signaling, target-engagement and epitope studies, and as a

defined isotype-matched comparator or positive control alongside other GDF15 tools. The material is manufactured to in-vivo research standards with low endotoxin and is offered in bulk milligram-to-gram quantities to support consistent, reproducible experiments across biology, characterization, and neutralization workflows. Lot-to-lot consistency supports longitudinal studies. GDF15 (growth differentiation factor 15; UniProt Q99988), also called MIC-1, NAG-1 or PLAB, is a distant, divergent member of the TGF-beta superfamily secreted as a disulfide-linked dimer. Circulating GDF15 rises during cellular stress, inflammation, aging, pregnancy, cardiometabolic disease and malignancy, making it a widely studied biomarker. Its principal characterized receptor is GFRAL (GDNF-family receptor alpha-like), whose expression is largely restricted to neurons of the area postrema and nucleus tractus solitarius in the hindbrain. GDF15 binding to GFRAL recruits the co-receptor RET, driving downstream AKT, ERK and PLC signaling that suppresses appetite and reduces body weight. In cancer, tumor-derived GDF15 contributes to cachexia and can dampen antitumor immunity, so neutralizing the ligand is being explored to restore checkpoint-inhibitor responsiveness and reverse wasting.

Other names: Macrophage inhibitory cytokine 1, MIC-1, NSAID-activated gene 1 protein, NAG-1, NSAID-regulated gene 1 protein, NRG-1, Placental TGF-beta, Placental bone morphogenetic protein, Prostate differentiation factor, Growth/differentiation factor 15, PDF, PLAB,

Specificity: Detects human GDF15

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.



Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks